Risk Tolerance and Meaningfulness Panel Overview

Interviewer: What does waiting two, three, or five years for a new therapy mean for someone living with Huntington’s Disease (HD)?

Participant Response: Living with HD and waiting for new therapies is unpredictable and creates uncertainty. You don’t know how quickly or severely symptoms will progress, or how much time you have before they start. Each day can feel like a ticking time bomb, making the wait feel hopeless and frustrating. Even a single year can feel significant, and the time lost is irreplaceable.

Interviewer: How well do current study endpoints reflect the patient experience? What additional patient-reported outcomes or measures could complement existing endpoints?

Participant Response: Current endpoints, like total functional capacity, are imperfect because ability is subjective. For example, I might say I can clean my house because it is clean, but in reality, I might be hiring someone to do it. Stress or the setting of a clinic visit can also affect answers. More specific, task-based questions and input from support persons or caregivers would give a more accurate assessment.

Interviewer: When a trial for a new treatment does not meet its primary endpoints but shows some benefit, how should regulators handle the uncertainty? Should conditional approval be considered?

Participant Response: We need strong data to show a treatment works, but people are not just data points. If a treatment is safe and provides some benefit, people should have the option to continue if they wish. Conditional approval should be considered, especially given the devastation when trials end and access to promising treatments is lost.

Interviewer: Should there be more emphasis on developing multiple new treatment options for HD, even if symptom management drugs already exist?

Participant Response: Yes, having multiple options is important because not everything works for everyone. Treatments need to address the many ways HD and related conditions show up. The more options available, the better, as people respond differently to different drugs.

Interviewer: What level and type of treatment risk is acceptable for a therapy that may slow progression but is unlikely to improve existing symptoms?

Participant Response: Risk tolerance is highly individual and can change over time or with disease progression. Some are willing to accept nearly any risk, but the decision also affects care partners and families. The level of acceptable risk depends on personal circumstances, stage of disease, and available support.

Interviewer: How does risk tolerance change with disease stage, age, or symptom presence?

Participant Response: Risk tolerance varies widely. Younger people may have more support, while others may take risks sooner if they feel they have less time. Willingness to accept risk can increase if someone loses independence or has financial stability through disability, or decrease if they fear losing what remains of their abilities.

Interviewer: Which risks are most concerning—serious but rare adverse events, common manageable side effects, uncertain long-term risks, or the chance of worsening symptoms?

Participant Response: The most concerning risk is the chance of worsening symptoms or daily quality of life, even if other side effects are manageable. Anything that negatively affects daily living or the family is a serious concern.

Interviewer: How much uncertainty about long-term safety or benefit would you accept for early access to promising treatments?

Participant Response: Tolerance for uncertainty depends on personal and family priorities, disease stage, and the hope for future generations. Many are willing to accept considerable uncertainty for early access, seeing it as a duty both to themselves and to others affected by HD.

Interviewer: Should placebo-controlled periods in trials be shortened, and could registry or observational data help?

Participant Response: Yes, placebo periods should be as short as possible because HD is progressive and time lost cannot be regained. Observational data from registries could help reduce placebo time and ensure that participants have access to active treatment sooner.

Interviewer: What specific benefits are most meaningful—maintaining independence, slowing decline, preserving cognition, or delaying milestones?

Participant Response: All these benefits are important. Quality of life and maintaining independence are especially valued, as losing independence is often the hardest part of the disease for both patients and families.

Interviewer: How do patients weigh treatment convenience against efficacy (e.g., oral vs. infusion, injection, or surgery)?

Participant Response: Convenience is important, but so is efficacy. Preferences depend on individual circumstances, support systems, and the stage of disease. For some, less invasive options are best; for others, more invasive treatments may be acceptable if they offer greater benefit.

Interviewer: How important are treatment reversibility and the frequency of safety monitoring?

Participant Response: Safety should always be prioritized. Patients want to be fully informed about risks, expectations, and what would happen if adverse events occur. Frequent monitoring and the ability to stop treatment are important to reduce burden and support commitment to trials.

Interviewer: What information do patients and caregivers need to make informed decisions when biomarker changes are encouraging but clinical benefit is uncertain?

Participant Response: Transparency and directness are key. Data should be accessible, clear, and easy to understand. More sensitive and specific data points should be used, and both the scientific implications and next steps should be clearly explained.

Interviewer: How do patients and caregivers balance the potential to slow HD progression against risks and treatment burden?

Participant Response: Quality of life is often prioritized over quantity. The decision can change over time, and having the ability to make choices as circumstances evolve is essential.

Interviewer: What is a fair and ethical timeframe to be on a possible placebo?

Participant Response: Shorter placebo periods are more ethical, as prolonged time on placebo means lost time that cannot be regained. Access to the study drug after the trial or using registry data to reduce placebo exposure is preferred.

Interviewer: How do patients and caregivers weigh different administration routes (oral, injection, self-injection, surgery) when considering effectiveness, risk, convenience, reversibility, and monitoring?

Participant Response: These choices are highly personal, affected by individual and family preferences, convenience, and the ability to manage treatment and monitoring. Stress, anxiety, and the practical aspects of administration are significant factors.

Interviewer: What factors influence the decision to participate in a clinical trial (e.g., placebo length, intervention method, travel, burden, open label extension)?

Participant Response: All these factors matter, and the decision is complex. Family planning, access to care, travel, the potential to rule out future trial participation, and available resources all play a role. The decision can feel overwhelming due to limited information and high stakes.

Interviewer: Does family planning influence your decision to participate in a clinical trial?

Participant Response: Yes, family planning is a major consideration. Protocols that address potential infertility, financial burdens, and the time commitment are important. Access to resources and clear information about options are needed.

Interviewer: What is the preferred method for receiving updates about clinical trials and programs?

Participant Response: A mix of methods is preferred, including live webinars, advocacy group websites, and face-to-face communication at events or support groups. Accessible, up-to-date, and easy-to-understand information is valued.

Interviewer: What aspects of a clinical trial would make participation easier? What could relieve the burden?

Participant Response: Reducing travel, financial burden, and time commitment helps. Flexible scheduling, more locations, combining trial visits with regular appointments, and clear communication are beneficial.

Interviewer: Do you feel a greater burden now that more trials are enrolling? Why or why not?

Participant Response: Yes, having more options can increase pressure to make the right choice, especially when information is limited. The risk of choosing a trial that doesn’t work or excludes future options is stressful. However, having choices is still seen as a significant improvement.

Interviewer: What is one thing you wish regulators understood about HD and clinical trials?

Participant Response: HD affects entire families, not just individuals. It is a generational, family disease with profound impact on daily life. Choice and autonomy are critical, and the role of caregivers and support persons is essential to successful participation.

Interviewer: What did it mean to you to see regulatory flexibility and accelerated approval?

Participant Response: It brought hope to the community, making it feel less like a death sentence. The opportunity for new treatments, even under accelerated pathways, is deeply meaningful and provides a sense of possibility